MedTrace Logo

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

NCT06574698 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-08-28

No results posted yet for this study

Summary

To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.

Conditions

Interventions

DRUG

Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy

Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy

Sponsors & Collaborators

  • Guangzhou Women and Children's Medical Center

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2029-12-31
Completion
2032-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06574698 on ClinicalTrials.gov